Moderna (MRNA) Stock
Healthcare sector company. Here's the price, business snapshot, and what's worth knowing about Moderna in October 2026.
Moderna, Inc. (MRNA) is a biotechnology company centred on messenger RNA (mRNA) technology, best known for its COVID‑19 vaccine. The company applies its platform to develop vaccines and therapeutics across infectious diseases (influenza, RSV, CMV) and oncology, aiming for faster design and scalable manufacturing. Investors should know Moderna’s prospects combine platform-driven upside with typical biotech risks: revenues can be lumpy, clinical trials are binary events, and regulatory approvals and competition (notably Pfizer/BioNTech) materially affect the outlook. The market capitalisation reflects the transition from pandemic-era demand to a broader commercial strategy. Moderna invests heavily in R&D and capacity, which can pressure margins in the near term but may support future growth if programmes succeed. This stock tends to be higher volatility and may suit investors with a longer timeframe and higher risk tolerance. This is general information, not personalised investment advice.
Moderna (MRNA) Stock Forecast
Analyst price target, next 12 months
$103.54
-45.4% vs today's $189.69
Price range over the last 12 months
Close to its 12-month high
Analysts covering Moderna have a consensus 12-month target of $103.54, below the current price of $189.69.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 7 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend holding Moderna's stock with a target price of $103.54, indicating limited growth potential.
Financial Health
Moderna is performing well with solid revenue and cash flow, though profit margins are moderate.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Platform-driven growth
Moderna’s mRNA platform can speed development and scale production, offering potential for new products — though trial outcomes and approvals remain uncertain.
Pipeline diversification
Programmes in flu, RSV, CMV and oncology could broaden revenue streams, but each faces clinical and regulatory hurdles that create binary outcomes.
Commercial dynamics
Post‑pandemic demand, pricing and competition shape future sales; market conditions can change quickly and past performance is no guarantee of future results.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
